- Global Pharma News & Resources

Growing global geriatric population will boost the muscle relaxant drugs market, forecast to grow at a CAGR of 6%

Noida, Uttar Pradesh, India, February 24 2021 (Wiredrelease) Report Ocean Pvt Ltd –:Global Muscle relaxant drugs Market is estimated to see healthy growth, pegged at a CAGR of ~6% during the forecast period 2020-2026. Growing geriatric populations globally who are more prone to musculoskeletal disorders are the primary factors driving the market’s growth. Moreover, increasing prevalence of pain and spasm conditions, increasing focus on the development of novel drugs for the treatment of spasm and pain, frequent product approvals, and a growing number of surgeries are the other factors that bolstered the market growth. However, the side effects associated with the muscle relaxant drugs are expected to restrain the development of muscle relaxant drugs sales in the coming years.

Request Sample Report at:

Growing Geriatric Population

Muscle pain is widespread in older adults. Older people suffer from many conditions such as polymyalgia rheumatic through their aging period, which causes muscle pain and stiffness in the upper arms, shoulders, thighs, and pelvic girdle. Furthermore, the world’s older population continues to grow at an unprecedented rate, and currently, 9% of people worldwide are aged 65 and over. As the world’s more aging population continues to grow at an unprecedented rate, it is expected that the demand for muscle relaxant drugs will rise in the coming years.

Sector Overview

Muscle relaxants are categorized under a diverse group of medicines that can relax or reduce muscle tension. These are mainly used to treat conditions such as spasms, hyperreflexia, and muscle pain. The two muscle relaxant types are available in the market are direct-acting muscle relaxants and centrally acting muscle relaxants. Direct-acting muscle relaxants are also known as neuromuscular blocking agents. These have no central nervous system activity and act by interfering with neurons’ transmission at the neuromuscular junction endplate.

The rise in the number of surgeries and the increased senior population is projected to drive the global muscle relaxant drugs market during the forecast period. Additionally, a rise in the prevalence of chronic lower back pain is anticipated to propel the global market during the forecast period. According to the WHO, the lifetime prevalence of non-specific lower back pain is estimated at 60% to 70% in industrialized countries. However, drugs’ side effects and abuse potential are likely to restrain the global muscle relaxant drugs market.

Segmentation Overview of the Global Muscle Relaxant Drugs Market

The muscle relaxant drugs market has been segmented into Drug Type, Route of Administration, Drug Class, and Distribution Channel. These major market segments are further categorized into various sub-segments to study the market in detail.

By Drug Type Outlook (Facial Muscle Relaxant, Skeletal Muscle Relaxant, Neuromuscular Relaxant)

By Route of Administration Outlook (Oral, Injectable)

By Drug Class Outlook (Peripherally Acting Muscle Relaxants, Centrally Acting Muscle Relaxants)

By Distribution Channel Outlook (Drug Stores, Hospitals, Clinics, Online Stores)

Key Players Insights

AbbVie, Inc., Sandoz, Inc. (Novartis AG), Abbott Laboratories, Pfizer, Inc., Merck & Co., Inc., MedPointe Pharmaceuticals, Meda Pharmaceuticals, Inc., Valeant Pharmaceutical International, Inc., Ipsen Biopharmaceuticals, Inc., and Acorda Therapeutics, Inc., among others, are some significant players included in the research study of the global muscle relaxant drugs market.

For Purchase Enquiry:

This content has been published by Report Ocean Pvt Ltd company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at

Editor Details

Last Updated: 24-Feb-2021